Quite an expensive settlement, but a settlement
26/06/20 -"We have taken into account the guided cash out in 2020 and 2021 for the announced settlements of the three litigations. Regarding the 15% tax shield Bayer also guided for, we remain rather more ..."
Pages
70
Language
English
Published on
26/06/20
You may also be interested by these reports :
11/03/26
BioNTech’s full-year results revealed sales surpassing expectations, although the operating loss was higher than anticipated. The 2026 sales guidance ...
11/03/26
While we acknowledge the upcoming HIV patent expiries (c.17% of sales) starting 2027-28, we remain encouraged by GSK’s execution ability as it ...
06/03/26
We have incorporated the 2025 reported figures and added a new forecast year (2028) to our model. Consequently, we have reduced the out-year sales ...
05/03/26
The Q4 results fell somewhat short of expectations, as Life Science and Healthcare witnessed decent growth, whereas the quarter was tough for ...